System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Mark S Freedman, MD is an expert in Neurology at Ottawa Hospital (Canada). As of October 2026, ScienceLeadR ranks Mark S Freedman in the top 1% of experts worldwide for Multiple Sclerosis and Autoimmune Diseases. Mark S Freedman has authored 545 publications, the most recent in 2026, and is an investigator in 41 clinical trials. SLR score: 2,009 (community average: 125). How the SLR is computed.

LeadR Profile

Mark S Freedman, MD Ottawa Hospital Canada
2 009 ScienceLeadR Reputation 2009

Unlock

Register Login
Network Map

Neurology

Subspecialties: Immunology - Biochemistry - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1990 - 2026
Source: PubMed

University of Ottawa

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 545

Citations

Citations: 42 601 1st author: 93 Last author: 95 Unique author: 22

Main journals

Neurology 136
Mult Scler 59
Mult Scler Relat Disord 35
Lancet Neurol 22
Can J Neurol Sci 20

Best Journals

N Engl J Med 8
Lancet Neurol 6
Science 3

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Long-term safety and efficacy of ponesimod, an oral S1P1 receptor modulator, in relapsing-remitting multiple sclerosis (RRMS): Results from randomized phase 2b core and extension studies spanning up to 13 years.
PMID 42561748 — sclerosis, multiple sclerosis, safety, therapeutics, wounds and injuries, multiple sclerosis, relapsing-remitting		Mult Scler Relat Disord20260
Patient reported outcomes in NMOSD reflect a high disease burden and do not correlate with the EDSS.
PMID 42116255 — depression, multiple sclerosis, pain, multiple chronic conditions, neuromyelitis optica, fatigue, sex, patient reported outcome measures, cost of illness, demography, generalized anxiety disorder		Mult Scler Relat Disord20260
Serum metabolic profile at clinical onset as predictor of multiple sclerosis activity and progression after 5 years.
PMID 42035447 — sclerosis, multiple sclerosis, epidemiology, serum, brain, cohort studies, metabolomics, prognosis		Mult Scler20260
Long-term safety and efficacy of ponesimod in participants with relapsing multiple sclerosis: results from the phase 3 OPTIMUM 5-year long term extension study.
PMID 41879928 — sclerosis, multiple sclerosis, safety, neurosurgery, therapeutics, neurology		J Neurol20260
Best practice recommendations for laboratory analysis and reporting of cerebrospinal fluid oligoclonal banding and associated tests for multiple sclerosis (MS): a consensus report from the harmonized CSF analysis for MS investigation (hCAMI) subcommittee of the Canadian society of clinical chemists (CSCC).
PMID 41692184 — research design, sclerosis, multiple sclerosis, laboratories, biochemistry, diagnosis		Clin Biochem20260

Clinical Studies 41

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 2

By phase:

Phase 3 23
Phase 2 9
N/A 4
Phase 4 4
Phase 2/Phase 3 1

By status:

Completed 36
Terminated 5

By type:

Interventional 38
Observational 3

By Monocentric/Multicentric:

monocentric 4
multicentric2to4 1
multicentric5to9 0
multicentricup10 36

Main Topics

Cohort/Consortium Investigators 3

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS